Summer 2014

New Hope for Deadly Breast Cancers

Researchers find promising target in battle against tough-to-treat tumors

By Taylor McNeil

Previous Next

Work done in the Sonenshein lab shows that the presence of ADAM8 protein is linked to the growth of the most aggressive breast cancers. Brown staining in image B marks ADAM8 in triple-negative tumor tissue, compared with image A, normal breast tissue. Photos: Courtesy of Sonenshein Lab/EMBO Press

Tufts researchers have identified a new target for treating particularly aggressive forms of breast cancer that could potentially save thousands of lives each year.

Gail Sonenshein, a professor of developmental, molecular and chemical biology at the School of Medicine, and her research team found that when they injected antibodies to a protein called ADAM8—essentially turning the protein off—in mice with triple-negative breast cancers, the tumors stopped growing and did not metastasize. The research, which was funded by the National Institutes of Health among other sources, was published in January in EMBO Molecular Medicine.

Scientists have identified three specific receptors that drive the growth of a large percentage of breast cancers. Treatments that interrupt the activity of these receptors have proven effective, but triple-negative breast cancers lack these three receptors. “Triple-negative breast cancers are incredibly aggressive,” Sonenshein says. “They tend to appear in younger women and in African-American women, and have a higher mortality rate, accounting for 25 percent of breast cancer deaths. There are chemotherapy and radiation treatments, which can have quite serious side effects and are not highly effective, but there are no targeted therapies.”

Over the last two decades, Sonenshein and her team have been trying to identify molecular factors that drive invasive breast cancers and could be used to develop more specific treatments. A few years ago, her lab identified ADAM8 in a screen for proteins that promote cell properties of aggressive breast cancers. Consistently, ADAM8 expression levels correlated with the severity of the disease and poor patient outcomes. ADAM8 was present in one third of triple-negative breast tumors and half of all breast cancer metastases.

“Triple-negative breast cancers are incredibly aggressive, accounting for 25% of breast cancer deaths.Gail Sonenshein

When the Sonenshein group reduced the amount of ADAM8 in breast cancer cells, they became less invasive but were still able to grow normally on plastic. Mathilde Romagnoli and Nora Mineva, postdoctoral research associates in Sonenshein’s lab, then set up a series of experiments in which triple-negative breast cancer cells were implanted in the mammary glands of mice. In the first experiment, they permanently removed ADAM8 from the triple-negative breast cancer cells. Tumors lacking ADAM8 grew only to a very small size, and no metastasis occurred. “It was a total surprise. We had expected only effects on tumor spread,” Sonenshein says.

Their studies have found that ADAM8 plays two roles. Once tumors start to grow and reach a critical mass, they stop growing if they don’t have adequate access to nutrients or oxygen. ADAM8 sends signals that help recruit new blood vessels to the tumor, a process called angiogenesis. The blood vessels then feed the tumor with the nutrients and oxygen required for its growth.

In addition, ADAM8 is necessary to activate proteins on the surface of the cancer cells that allow them to interact with the blood vessels. This gives them the means to enter and exit blood vessels, essentially promoting metastasis. When Irene Georgakoudi, Sonenshein’s collaborator in Tufts’ Department of Biomedical Engineering, and her colleagues tested the blood from the mice with tumors lacking ADAM8, there were very few tumor cells in circulation. 

Target Practice

To test whether ADAM8 would respond to antibody therapy, Romagnoli and Mineva used commercially available antibodies specific for the outside active portions of ADAM8. In animals that received antibodies to ADAM8, the tumors grew much more slowly, and most animals had no metastasis. The results “validate ADAM8 as one of the first targets for triple-negative breast cancers,” Sonenshein says.

Sonenshein is now investigating various means to produce human ADAM8 antibodies that can be used to treat patients. Once these antibodies are developed, her group will need to test their effectiveness on the mouse models they have established, as well as on patient tumor samples transplanted into mice, a procedure called patient xenografting.

Sonenshein will collaborate with a researcher at Baylor University for this work. Toxicity tests to make sure that turning off ADAM8 wouldn’t have any negative consequences would also need to be done before moving any antibody to clinical trials in humans. 

“If we can make an effective human ADAM8 antibody, and if all of the testing goes well, women with triple-negative ADAM8-positive tumors could be treated with this antibody and would have a more effective and less-toxic option than high-dose chemotherapy or radiation,” says Sonenshein.

“At this point, ADAM8 is one of the best targets you could actually look for, because it appears to have no essential function” that would be missed if it were removed, Sonenshein says.

Taylor McNeil can be reached at

Top Stories

The Greater Good

Prompted by a new curricular requirement, more medical students than ever are volunteering in the community

The Boss Who Barked

He could be brusque and opinionated. But however he carried himself, Tufts professor Louis Weinstein ranked as a founding father of the field of infectious diseases

Father, Brother, Son

Tufts Medical School has touched three generations of this writer’s family

Editor's Picks

A Digital Version of You

Geneticist J. Craig Venter says synthetic biology and big data will revolutionize our understanding of aging

TB on the Comeback Trail

Microbiologist works to decipher the defenses of the centuries-old bacteria

Antidepressants and Early Birth

Pregnant women and their doctors should carefully consider potential effects of medication, study finds

The First Spark

Targeted philanthropy supports early stages of promising research into health challenges

Tell Me More

Because interviewing patients effectively is such a precious skill in medicine, Tufts has redoubled its emphasis on teaching students how to do it right

Lessons from Above

Psychiatrist Ronald Pies culls the wisdom of Judaism, Buddhism and Stoicism for advice in coping with life’s vicissitudes